Fibrobiologics, INC 8-K filings

FibroBiologics has entered into a Standby Equity Purchase Agreement with YA II PN, LTD., securing up to $25 million in funding over two years.

FibroBiologics has terminated its share purchase agreement with GEM, issuing 1,152,074 shares at $2.17 each for $2.5 million, while also canceling outstanding warrants and waiving a $1.5 million commitment fee.

FibroBiologics, Inc. has announced the resignation of its Chief Financial Officer, Mark Andersen, and the appointment of Robert Hoffman as interim CFO, effective October 30, 2024.

FibroBiologics has established a long-term agreement with Charles River Laboratories for development and manufacturing services, outlining a framework for future project-specific collaborations.

FibroBiologics, Inc. held its annual meeting, amended its certificate of incorporation, and elected directors.

FibroBiologics sold 100,000 shares of its common stock to GEM Global Yield LLC, generating $451,000 in gross proceeds.

FibroBiologics, Inc. has amended and restated its bylaws to address universal proxy rules, align with its charter, and remove outdated provisions.

FibroBiologics reports positive pre-clinical results for its wound healing therapy and provides updates on its multiple sclerosis and degenerative disc disease programs, including plans for upcoming clinical trials.

FibroBiologics announced the presentation of preclinical and phase 0/1 clinical trial data at the 2024 ACTRIMS Forum, showcasing the potential of human dermal fibroblasts for treating multiple sclerosis.

FibroBiologics announced preclinical data showing their human dermal fibroblast spheroids significantly reduced psoriasis severity in a mouse model, demonstrating potential for a new cell-based therapy.

FibroBiologics has announced the issuance of three new United States patents related to its fibroblast technology, further strengthening its intellectual property portfolio.

FibroBiologics has announced the issuance of three new patents from the Japan Patent Office, further solidifying their position in fibroblast technology.

FibroBiologics, a clinical-stage biotechnology company, has begun trading on the Nasdaq Global Market under the ticker symbol FBLG after a direct listing.